Skip to main content

Table 3 Supplied amounts of Pt and Pt, As and Se in 24-h urine results for the group patients treated with Pt-based drugs and control group treated without Pt-based drug and the baseline group (a)

From: Urinary excretion of platinum, arsenic and selenium of cancer patients from the Antofagasta region in Chile treated with platinum-based drugs

Groups

Type of cancer

Parameter

PtSupp(mg)

Pt (μg)

Se (μg)

As (ng)

Cisplatin (Group 1)

Lung

X

163.0

35.3

3.62

127.0

Med

156.0

28.2

1.28

23.5

DS

66.6

25.9

6.45

267.0

n

32

32

24

21

Min

39.1

3.94

0.208

1.88

Max

263.0

90.4

22.0

1180.0

Cisplatin (Group 2)

Other

X

174.0

40.1

1.35

216.0

Med

120.0

32.5

1.22

71.0

DS

324.0

36.1

0.717

424.0

n

47

47

36

31

Min

31.6

0.760

0.354

18.8

Max

2297.0

175.0

2.84

2300.0

Carboplatin (Group 3)

Other

X

695.0

262.0

1.59

40.8

Med

a

a

a

a

DS

189.0

201.0

0.711

46.9

n

11

11

9

6

Min

433.0

9.80

0.516

2.53

Max

917.0

680.0

2.52

121.0

Control 1 (b) (Group 4)

Other

X

  

1.77

62.0

Med

  

a

a

DS

  

1.14

59.4

n

  

7

2

Min

  

0.333

20.0

Max

  

3.29

104.0

Control 2 (c) (Group 5)

Lung and other

X

  

1.47

48.2

  

Med

  

a

a

  

DS

  

0.58

1.56

  

n

  

9

2

  

Min

  

0.45

47.1

  

Max

  

2.16

49.3

  1. Amounts of supplied Pt and Pt, As and Se in 24-h urine samples.
  2. Supp, Supplied; X, mean; Med, Median; SD, Standard deviation; n, number of cases; Min, Minimum value; Max, Maximum value; (a) due the small number of cases, the median values were not reported; (b) non platinum drugs treatment; (c) patients without chemotherapy (two gastric cancer, two bladder cancer and five lung cancer).